Sorry man
Response from developer
Thank you for your feedback, we are Sorry to hear that, definitely not the kind of experience we want for our users. We appreciate the feedback and will keep working to improve.

This app offers a structured approach to learning the Arabic alphabet. It includes audio pronunciation, writing practice, quizzes, and interactive puzzles to help users master the letters and their sounds.
1.2
December 1, 2024
- fix bug errors - app improvement
Yearly plan to unlock more features
Thank you for your feedback, we are Sorry to hear that, definitely not the kind of experience we want for our users. We appreciate the feedback and will keep working to improve.
Learn Arabic Alphabet features high-quality voice-overs for each letter and its examples, allowing users to listen and learn correct pronunciation. English subtitles are also provided for clarity.
Yes, the app includes a dedicated feature to learn and practice writing Arabic alphabet letters. This hands-on approach helps reinforce learning.
Learn Arabic Alphabet offers three subscription plans: a weekly plan for $1.99, a monthly plan for $3.99, and an annual plan for $17.99. All features are unlocked with a subscription.
Subscriptions automatically renew unless auto-renewal is turned off at least 24 hours before the end of the current payment period. You can manage your subscription preferences in your iTunes Account Settings.
With an age rating of 4+, Learn Arabic Alphabet is designed to be accessible for young learners. The interactive puzzles and clear audio make it engaging for children.
The latest version of Learn Arabic Alphabet is 1.2, and it was last updated on December 1, 2024. Updates typically include improvements and new content to enhance the learning experience.
Learn Arabic Alphabet is available on both iPhone and iPad, making it convenient for users on Apple's mobile platforms.
The app description mentions that any unused portion of a free trial period, if offered, will be forfeited when a user purchases a subscription. Specific details on trial availability are not provided.